India Market Growth and Financial Performance
India: Outperforming market growth
India Rx business grew 12.9% in Q3FY24 (1.6x IPM
growth)
India Sales (INR mn)
Leveraging therapy leadership; Added 7
new divisions in last 12 months
15,213
14,786
Q3FY23
Q4FY23
16,384
Q1FY24
16,915
17,251
Q2FY24
Q3FY24
LUPIN
#2 rank
Respiratory
#3 rank
#3 rank
Diabetes Care
Cardiac
•
Chronic share ~62% of sales
Ranked #1 in New Product introductions in IPM²
.
Continued Outperformance in Respiratory, Gl and
Gynaecology segment
• India Rx business grew 10% YoY in 9MFY24 vs IPM
•
growth of 8.2% (1.2x IPM growth)
Key segments including Respiratory, GI & Gynaecology
growing faster than market¹
• Q3 Anti-diabetes Non-IL growth 11.8% vs Segment 5.5% 1
• Q3 In-licensed % of India sales: 10.4% Q3 vs 15% in FY23
.
1 IQVIA Oct-Dec-23
2. IQVIA MAT Dec-23
Gaining significant launch momentum with 7 new
introductions in the quarter
1 in
Diabetes Care
•
Key New Launches
1 in
Cardiac
2 in
1 in
Respiratory
Neuro/CNS
Valentas® Ranked #1 new launch in Cardiac²
•
Launched 21 products in 9MFY24
7View entire presentation